Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Nerve Block: later-stage trial registry

1 of 5 indexed Nerve Block trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Nerve Block: 5 US clinical trials tracked, 1 recruiting.

Nerve Block is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is George Macrinici, running 1 of these trials.

Enrollment posture brief

Registry condition nerve-block

OPEN 1 | RECR 20% | LATE 1 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Nerve Block (this)20%
Open-enrollment share among volume-matched conditions near Nerve Block

Nerve Block lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nerve Block on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nerve Block is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Nerve Block research.

    George Macrinici accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Nerve Block trials plan to enrol fewer than 100 people.

    Median target enrolment is 64 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Nerve Block research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Named interventions

Most-linked intervention names on Nerve Block records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Femoral Nerve Block, Bupivacaine Procedure
1 trials
Adductor Canal Block, Bupivacaine Procedure
1 trials
30ml bolus of bupivacaine Drug
1 trials
Pudendal block Procedure
1 trials
Pericapsular injection Procedure
1 trials
Lumbar Plexus BLock Procedure
1 trials
Exparel Single Shot Interscalene Block Procedure
1 trials
Interscalene Catheter Procedure
1 trials

US sites by state

Facility locations filed on Nerve Block trials. A trial with sites in several states counts in each.

Pennsylvania 1 trials
Ohio 1 trials
Maryland 1 trials
Illinois 1 trials
Iowa 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nerve Block page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nerve Block condition card totals 5 registered trials; most-linked intervention Femoral Nerve Block, Bupivacaine; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.